China's State Council rolled out a three-decree suite reshaping cross-border compliance: Order No. 837 (Outbound Investment, effective July 1, 2026), Decree No. 835 (Countering Foreign Extraterritorial Jurisdiction + new "Malicious Entity List," effective Apr 13, 2026), and Decree No. 834 (Industrial & Supply-Chain Security, effective Apr 7, 2026). Together they add outbound investment approval/filing, tech & data export controls, an overseas security review, and counter-sanctions exposure for cross-border business. This assessment has been updated to reflect these rules. 中国国务院第834/835/837号令三项新规已施行：对外投资核准备案、反制裁"恶意实体清单"与产业链供应链安全规定已更新至本评估。
Cross-border business between the United States and China is becoming more complex, more regulated, and more politically sensitive. This free assessment helps executives, investors, and operators identify exposure across trade, technology, supply chains, investment, and data flows before hidden risks become costly mistakes.
🆕 Updated for China State Council Order No. 837 (July 1, 2026)
This assessment now covers China's new outbound investment approval & filing obligations, stricter technology/data export controls (Art.13), overseas investment security review (Art.15), and counter-sanctions exposure (Arts.24–25). 本评估已更新，覆盖中国对外投资新规。
Free assessment. No obligation.
Export Controls
BIS regulations, Entity List, EAR restrictions affecting technology transfers
Investment Scrutiny
CFIUS review, outbound investment restrictions, foreign ownership rules
Data & Tech Governance
Cross-border data flows, PIPL compliance, software and algorithm controls (Art.13 Order 837)
Supply Chain Compliance
Forced labor laws, UFLPA traceability, sourcing and partner diligence
Outbound Investment Filing (NEW)
China State Council Order No. 837: approval/filing requirements for outbound investors (effective July 1, 2026)
Counter-Sanctions Exposure
China retaliation list risk — foreign orgs restricting Chinese investors may face counter-measures (Arts.24-25)
Governance Readiness
Internal procedures, counterparty screening, regulatory review maturity
This assessment reflects the latest developments through September 2026. The policy environment continues to shift rapidly — these are the changes most likely to affect your cross-border exposure today.
U.S. Tariffs · Section 122
Reciprocal tariffs reconfigured under Section 122 authority
After the Supreme Court's IEEPA ruling, the administration shifted to Section 122, with the central estimate near 9.1%. The Nov 2025 U.S.–China agreement suspended heightened reciprocal tariffs, but the regime is now more discretionary and less predictable — origin and classification are central to every shipment. (Brookings, USTR, June 2026)
Export Controls · BIS Enforcement
2026 enforcement surge targets chip exports to SMIC
BIS opened 2026 with major penalties: Applied Materials $252M (second-largest BIS penalty ever), Exyte $1.5M, Solventum, and Coastal PVA. Key lesson: "substantial transformation" abroad is not a defense under the EAR, and the Foreign-Direct Product Rule reaches foreign-made items using U.S. technology. (Kharon / BIS, May 2026)
China · Draft Financial Law
China's first overarching financial statute released for comment
On March 20, 2026, MOJ, PBOC, NFRA, CSRC & SAFE released the Draft Financial Law (11 chapters, 95 articles). It broadens the regulatory perimeter from "all financial business" to "all financial activities," formally recognizes the digital RMB (Art. 12), and strengthens shareholder accountability — signaling a financial system less dependent on the Western model. (WilmerHale, April 2026)
Sanctions · OFAC 2025–26
1,300+ designations; $266M in enforcement penalties
OFAC issued 14 enforcement actions totaling $266M in 2025 (led by a $215M GVA Capital penalty), prioritizing cartels, SE Asia scam networks, Iran's shadow fleet/banking, and China. The clear signal: companies must look past legal formalities to the underlying economic reality of counterparties and structures. (Paul Weiss / CCI, March 2026)
China · Counter-Sanctions (Decree 835)
New "Malicious Entity List" & counter-extraterritorial regime
Effective Apr 13, 2026, Decree No. 835 operationalizes the Anti-Foreign Sanctions Law: the Ministry of Justice can identify "improper" foreign measures, issue Prohibition Execution Orders, and list foreign entities that "promote" foreign sanctions on a Malicious Entity List — triggering entry bans, asset freezes, data-transfer and trade bans. MNCs face conflict-of-laws exposure. In June 2026 China added 10 US and 40 Japanese firms to its export-control entity lists. (MoFo / Mayer Brown, 2026)
China · Supply-Chain Security (Decree 834)
Scrutiny of de-risking, supply-chain mapping & audits
Effective Apr 7, 2026, Decree No. 834 is China's first industrial & supply-chain security framework — monitoring of "key sectors" (chips, machine tools, advanced materials, biomanufacturing) and scrutiny of decisions to exit, replace suppliers, or suspend services tied to foreign sanctions. China entities must implement countermeasures; conflict-of-laws risk is rising. (Sidley / Norton Rose Fulbright, 2026)
UFLPA · Entity List Expansion (July 2026)
DHS adds 43 companies — total now 144+; sectors expanded
On July 31, 2026, DHS added 43 Chinese companies to the UFLPA Entity List, bringing the total to 144+. Enforcement no longer targets just cotton, tomatoes, and polysilicon — priority sectors now include aluminum, copper, steel, lithium-ion batteries, electronics, tires, and vinyl products. Any XUAR-sourced input anywhere in the supply chain creates import-ban risk. (DHS / CBP, July 2026)
U.S. Tariffs · Section 301 Forced Labor (July 2026)
USTR imposes 10–12.5% tariffs on 60 trading partners
On July 23, 2026, USTR concluded a Section 301 investigation finding 60 economies fail to block forced-labor imports, imposing 10.0–12.5% across-the-board tariffs. A separate Section 301 investigation into manufacturing overcapacity (16 economies including China, initiated March 11, 2026) is ongoing. The Trump-Xi agreement caps new China tariffs at 20%, leaving ~7.5% headroom. (USTR / CSIS, July 2026)
Export Controls · AI Diffusion Rule Rescinded
Biden AI Diffusion Rule rescinded; chip controls strengthened
The Trump Administration rescinded the Biden-era AI Diffusion Rule while rolling out stronger chip-related export controls. BIS added 42 PRC entities in March 2025 and 23 more in September 2025 to the Entity List. Nvidia's H20 GPU now requires a license (approved under controlled conditions). The VEU loophole allowing foreign firms to export semiconductor equipment to China license-free has been closed. (BIS / CRS, 2025–2026)
China · Exit & Entry Regulations (Decree 841)
New exit/entry framework now in force (Sept 15, 2026)
Effective September 15, 2026, State Council Decree No. 841 significantly updates China's exit and entry framework: stronger verification of visa, entry, stay, and residence applications; enhanced oversight of immigration-related activities; and a new regulatory framework for immigration service providers. Foreign investors and expatriate personnel face stricter documentation and compliance requirements. (DLA Piper / Fragomen / Eiger Law, 2026)
The greatest risk is often not the issue already on your radar, but the one that was never screened before a shipment, partnership, investment, or expansion plan moved forward.
U.S. tariffs have moved from fixed rules to presidential discretion — origin, classification, and eligibility now drive every sourcing and pricing decision
BIS's 2026 chip-enforcement surge produced the second-largest export-control penalty in U.S. history ($252M) — 'substantial transformation' is not a defense under the EAR
DHS added 43 companies to the UFLPA Entity List on July 31, 2026 (total 144+); enforcement sectors expanded beyond cotton/tomatoes/polysilicon to aluminum, copper, steel, batteries, and electronics
USTR imposed 10–12.5% Section 301 tariffs on 60 trading partners for forced labor (July 23, 2026); a separate overcapacity investigation targeting China is ongoing
China's Exit & Entry Regulations (Decree No. 841) took effect September 15, 2026 — stricter visa, entry, stay & residence verification now in force for foreign investors and expatriate personnel
OFAC sanctioned 1,300+ targets in 2025 and expects companies to look past legal formalities to the underlying economic reality of every counterparty
Sector-specific restrictions can affect even companies with limited direct China exposure if they touch strategic supply chains or technology flows
"This assessment helped us identify two compliance blind spots before we deepened a supplier relationship. It gave our leadership team a clearer view of what needed legal review and what was simply noise."
Operations Executive, U.S. Manufacturing Group
"What we valued most was the structure. The report turned a politically charged topic into practical business language and helped us prioritize action."
Managing Director, Cross-Border Investment Fund
"The tool quickly highlighted issues our internal team had not fully organized yet. It was a useful first step before engaging outside counsel."
General Counsel, Technology Company
Is this legal advice?
No. This assessment is informational and strategic in nature. It is designed to help identify issues and pressure points, but it does not replace legal advice or formal compliance review.
Who should take this assessment?
It is best suited for executives, investors, compliance-aware operators, and decision-makers with active or planned business exposure between the United States and China.
What do I receive after completing it?
You receive a structured compliance risk report with an overall score, dimension breakdown, issue flags, and suggested next steps. The full report is unlocked after contact information is submitted.
Will my information be shared?
No. Your information is used only for assessment delivery and follow-up by Artisan Business Group.
What if we need deeper help?
Artisan Business Group can provide targeted reviews, executive briefings, and advisory support for short-term or longer-term cross-border assignments.
Take the free Compliance Risk Assessment to identify where U.S.–China policy and regulatory exposure may already be affecting your decisions.
Free assessment. No obligation.